Incretin Atlas › Trials › OUTSTAND-2 (HRS-7535-302, NCT06589765)
OUTSTAND-2 (HRS-7535-302, NCT06589765)
HRS-7535 · t2d
Design
- Molecule(s)
- HRS-7535
- Population
- t2d
- Official title
- A Study of HRS-7535 Compared With Dapagliflozin in Adult Participants With Type 2 Diabetes and Inadequately Controlled With Metformin
- Sponsor
- Shandong Suncadia Medicine Co., Ltd.
- Phase
- 3
- Registry status
- completed · 2024-09 → 2026-05
- Participants
- 810
- Duration
- 32 weeks
- Registry
- NCT06589765
Results by arm
| Arm | Population | Weeks | n | Weight, efficacy | Weight, treatment-policy | HbA1c, pp | AE discontinuation, % | Any discontinuation, % | Nausea, % | Vomiting, % | SAE, % | SBP, mmHg | Status |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 30 mg vs dapagliflozin 10 mg: HbA1c -1.28 | t2d china | 32 | 810 | — | — | −1.6 | 4.0 | — | — | — | — | — | press release |
| 60 mg vs dapagliflozin 10 mg: HbA1c -1.28 | t2d china | 32 | 810 | — | — | −1.5 | 3.9 | — | — | — | — | — | press release |
Weight: percent change from baseline, drug vs placebo or comparator, Δ = difference in percentage points. Efficacy estimand = effect while on treatment (hypothetical strategy); treatment-policy = all randomised participants regardless of adherence (ITT). AE discontinuation = stopped study drug for any adverse event. Hover a status for its definition.
Verbatim quotes from the source (4)
- 30 mg · hba1c · press release
Based on the efficacy estimand^3, the reductions in HbA1c from baseline for the HRS-7535 30 mg, 60 mg, and 90 mg groups and the dapagliflozin 10 mg group were 1.58%, 1.50%, 1.68%, and 1.28%, respectively.
- 30 mg · ae_dc · abstract
Adverse events leading to discontinuation occurred in 4.0%, 3.9% and 3.9% versus 1.0%
- 60 mg · hba1c · press release
Based on the efficacy estimand^3, the reductions in HbA1c from baseline for the HRS-7535 30 mg, 60 mg, and 90 mg groups and the dapagliflozin 10 mg group were 1.58%, 1.50%, 1.68%, and 1.28%, respectively.
- 60 mg · ae_dc · abstract
Adverse events leading to discontinuation occurred in 4.0%, 3.9% and 3.9% versus 1.0%
Primary sources
- EASD 2026 Annual Meeting; 2026 Sep 29–Oct 3; Milan. Abstract easd66823.
- Kailera / Hengrui. Kailera Therapeutics Announces Positive Topline Data from Two Hengrui Pharma Phase 3 Clinical Trials of HRS-7535/KAI-7535 (HARBOR-1, OUTSTAND-2) (GlobeNewswire via BioSpace) [press release]. 2026-07-07. Available from: https://www.biospace.com/press-releases/kailera-therapeutics-announces-positive-topline-data-from-two-hengrui-pharma-phase-3-clinical-trials-of-oral-small-molecule-glp-1-receptor-agonist-hrs-7535-kai-7535
- ClinicalTrials.gov NCT06589765
How to cite this page
Medical Adviser's Group. Incretin Atlas: OUTSTAND-2 (HRS-7535-302, NCT06589765). Data cut 12 November 2026. https://docs.mdwrt.app/infographics/incretin-atlas/trials/outstand-2/ Data: doi:10.5281/zenodo.23473913. Accessed 16 November 2026.
Cite the primary publication for any single result; every value above links to it.